ASCO 2023 Kidney Cancer

Viewing 1-20 of 32 articles

ASCO 2023: When Is Stereotactic Ablative Body Radiotherapy an Option?

ASCO 2023: The Role of Cytoreductive Nephrectomy and Surgical Metastatectomy

ASCO 2023: When to Play the Systemic Therapy Card

ASCO 2023: Doublet and Triplet Therapy for Metastatic RCC: Factors That Influence Decision-Making

ASCO 2023: Doublet and Triplet Therapy for Metastatic RCC: The Case for Triplet Therapy

ASCO 2023: Doublet and Triplet Therapy for Metastatic RCC: The Case for Doublet Therapy

ASCO 2023: Discussant: Combination Therapies Come of Age in Kidney Cancer

ASCO 2023: Final Prespecified Overall Survival Analysis of CLEAR: 4-Year Follow-up of Lenvatinib + Pembrolizumab vs Sunitinib in Patients with Advanced RCC

ASCO 2023: Pembrolizumab + Axitinib Versus Sunitinib as First-Line Therapy for Advanced Clear Cell RCC: 5-Year Analysis of KEYNOTE-426

ASCO 2023: Efficacy and Safety of Atezolizumab + Cabozantinib vs Cabozantinib Alone After Progression with Prior Immune Checkpoint Inhibitor Treatment in Metastatic RCC: Primary PFS Analysis from the Phase 3, Randomized, Open-Label CONTACT-03 Study

ASCO 2023: NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Patients with Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

ASCO 2023: LITESPARK-024: Randomized Phase 1/2 Study of Belzutifan with or Without Palbociclib for Treatment of Advanced Renal Cell Carcinoma (RCC)

ASCO 2023: Poster Discussant: Adding Clarity to Non-Clear Cell Carcinoma

ASCO 2023: Pathologic Concordance Rate and Outcomes by Histologic Subtype in Advanced Papillary Renal Cell Carcinoma: An Analysis from the SWOG S1500 (PAPMET) Trial

ASCO 2023: Phase 1b/2 Study of Combination 177Lu Girentuximab + Cabozantinib and Nivolumab in Treatment Naïve Patients with Advanced Clear Cell RCC

ASCO 2023: Efficacy of First-Line Immunotherapy - Based Regimens in Patients with Sarcomatoid And/or Rhabdoid Metastatic Non-Clear Cell Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consort

ASCO 2023: First-Line Lenvatinib + Pembrolizumab Treatment Across Non-Clear Cell Renal Cell Carcinomas: Results of the Phase 2 KEYNOTE-B61 Study

ASCO 2023: Phase II Study of Cabozantinib with Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma with Variant Histologies

ASCO 2023: CABOSUN II: Results from a Phase 2, Open-Label, Multi-Center Randomized Study of Cabozantinib vs. Sunitinib for Non-Clear Cell RCC

ASCO 2023: Real-World Outcomes Among Patients with Advanced/metastatic RCC Treated with Cabozantinib or Other TKIs After Checkpoint Inhibitor Therapy

1
2